Education and Training
Efficacy of a Structured Weight Loss Program in Overweight Women With a History of Recurrent Pregnancy Loss
Overweight and obesity has been associated with a number of adverse pregnancy outcomes in women of reproductive age, including infertility and early pregnancy loss. Recent data suggests that overweight and obese patients are also at increased risk of recurrent pregnancy loss (RPL), a devastating condition that affects 1% of the fertile population.
The investigators propose a prospective, randomized controlled trial in which overweight and obese patients with unexplained recurrent pregnancy loss are enrolled in a structured, 6 month, weight loss program or provided routine counseling regarding the importance of weight loss. Pregnancy outcomes will then be followed to assess miscarriage rates. Metabolic outcomes, such as lipid and glucose profiles, will also be evaluated.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Structured Weight Loss Program
- behavioral: Routine Weight Loss Counseling
Eligibility
Inclusion Criteria:
1. Unexplained recurrent pregnancy loss (2 or more prior miscarriages)
2. BMI >=25 kg/m2
3. Prepared to take 3 months ¡®time out¡± from attempting to conceive
4. Ability to attend a one hour initial, then 30 minute follow-up nutrition/monitoring
session - once per week for one month, then every other week for 2 months, then once
then once per month for 3 months.
Exclusion Criteria:
1. Age >=40 years
2. Diagnosis of Type 1 or Type 2 Diabetes as defined by a fasting glucose >=126, or 2
hour glucose >=200 by a 75 gram oral glucose challenge
3. Presence of an endocrine condition such as hyperprolactinemia, Cushing¡-s syndrome or
untreated thyroid disease (defined as a TSH outside of the laboratory determined
normal range)
4. Desire to continue attempts to conceive for the duration of the program
5. History of bariatric surgery
6. Use of over-the-counter or prescribed weight loss medications with the exception of
metformin
7. Enrollment in another clinical trial (excluding surveys)
Ages Eligible for Study
18 Years - 39 Years
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jamie Masie, MD
650-498-7408
Not Recruiting